NCT00772863CompletedPhase 2
The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 37
- Locations
- 2
- Primary Endpoint
- Efficacy by response rate according to RECIST criteria and safety
Study Overview
Brief Summary
The purpose of this study is to assess the efficacy and the safety of the treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically/cytologically confirmed, optimally debulked stage III-IV epithelial ovarian cancer excluding clear cell histology.
- •ECOG Performance Status is 0-2
- •No prior chemotherapy for this malignancy,
- •Acceptable hematological profile (as defined by a leukocyte count ≥ 3000/mm3, a platelet count ≥ 100.000mm3 and Hb ≥ 9g/100mL), and adequate renal function (as defined by serum creatinine ≤ 1.5mg/dl or creatinine clearance by formulation ≥ 60 mL/min), and hepatic function (as defined by bilirubin ≤ 1.5 x maximum normal value even with hepatic metastasis; transaminases (ALT, AST) ≤ 1.5 x maximum normal value; alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone metastasis)
Exclusion Criteria
- •Concomitant use of another anti-cancer therapy
- •Unstable medical condition that makes the patient unable to take part in a clinical study (congestive heart failure, serious arrythmia, uncontrolled diabetes mellitus), history of myocardial infarction within last 3 months, massive pleural, peritoneal or pericardial effusion; or presence of serious uncontrolled infection.
- •Presence of other tumours different from basal cell carcinoma of the skin.
- •Pregnancy or breastfeeding. In women of childbearing potential and in men, an adequate contraceptive method must be used
- •Social or psychological condition that render the patient inadequate for the follow-up of the study
- •Contraindication for any of the study drugs (e.g. history of hypersensitivity to any of the ingredients of the study drugs)
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Outcomes
Primary Outcomes
Efficacy by response rate according to RECIST criteria and safety
Time Frame: After the 2nd cycle, 4th cycle and 8th cycle and at the follow up period
Secondary Outcomes
- Time to disease progression or relapse(Until progression througout the study)
- Survival time(Througout the study)
- Quality of life based on the questionnaire EORTC QLQ-C30 filled by the patients(Prior to entry, after completion of treatment and at the first follow-up visit)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer Disease (AD)NCT03518073Eli Lilly and Company360
Completed
Phase 3
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)Crohn's DiseaseNCT00805766Tanabe Pharma Corporation39
Active, not recruiting
Not Applicable
Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight WearMyopiaNCT06009458Acuity Polymers, Inc.387
Completed
Phase 2
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune SystemCOVID-19NCT05438602Pfizer157
Unknown
Not Applicable
Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced GliomaAdvanced GliomaComplication of Chimeric Antigen Receptor (CAR-T) Cell TherapyNCT05752877Second Affiliated Hospital of Soochow University12